Kohjin Bio Co.,Ltd. (177A) Price & Analysis

Compare

0 Followers

177A Stock Chart & Stats

¥1525.00

-¥17.00(-1.03%)

At close: Jan 08 4:00 PM EST

¥1525.00

-¥17.00(-1.03%)

Day’s Range― - ―

52-Week Range¥1,161.00 - ¥2,020.00

Previous CloseN/A

Volume7.50K

Average Volume (3M)3.64K

Market Cap

¥6.23B

Enterprise Value¥6.14B

Total Cash (Recent Filing)¥3.10B

Total Debt (Recent Filing)¥1.99B

Price to Earnings (P/E)24.5

Beta0.83

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.62%

Share Statistics

EPS (TTM)15.18

Shares Outstanding5,111,600

10 Day Avg. Volume4,170

30 Day Avg. Volume3,643

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)1.55

Price to Sales (P/S)1.72

P/FCF Ratio318.77

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Profitability MarginsKohjin Bio's high gross and operating margins point to sustainable cost control and pricing power in its business lines. Robust EBIT and EBITDA margins provide recurring internal cash for R&D and operations, helping the company absorb shocks and reinvest for durable growth over months.

Conservative Capital StructureA strong equity ratio and low leverage indicate durable capitalization and financial flexibility. With ROE near 14%, the company demonstrates efficient capital use while retaining the ability to fund projects, sustain operations, or respond to industry stress without excessive refinancing risk.

Improving Cash Generation TrendsOperating cash conversion above 1.0 and positive FCF growth show improving cash generation quality. This trend enhances the firm's ability to fund capex, support working capital, and gradually strengthen liquidity, reducing reliance on external funding over the medium term.

Bears Say

Operational Earnings VolatilityDocumented EBIT volatility signals persistent operational variability that can reduce predictability of earnings and cash flow. Such fluctuations raise execution risk, complicate budgeting and investment decisions, and could depress stakeholder confidence if not stabilized over successive quarters.

Low Free Cash Flow ConversionA very low FCF-to-net-income ratio means reported profits translate poorly into discretionary cash. This constrains the company’s ability to self-fund expansion, pay sustained dividends, or build reserves, increasing dependency on operational improvement or external financing to support strategic initiatives.

Historical EPS DeclineSignificant negative historical EPS growth points to prior deterioration in per-share earnings, which may reflect margin pressure, one-off items, or other structural issues. Even with recent profitability gains, the negative EPS trend is a legacy risk that must be addressed to ensure sustainable shareholder returns.

177A FAQ

What was Kohjin Bio Co.,Ltd.’s price range in the past 12 months?

Kohjin Bio Co.,Ltd. lowest stock price was ¥1161.00 and its highest was ¥2020.00 in the past 12 months.

What is Kohjin Bio Co.,Ltd.’s market cap?

Kohjin Bio Co.,Ltd.’s market cap is ¥6.23B.

When is Kohjin Bio Co.,Ltd.’s upcoming earnings report date?

Kohjin Bio Co.,Ltd.’s upcoming earnings report date is May 20, 2026 which is in 72 days.

How were Kohjin Bio Co.,Ltd.’s earnings last quarter?

Kohjin Bio Co.,Ltd. released its earnings results on Feb 13, 2026. The company reported ¥15.18 earnings per share for the quarter, beating the consensus estimate of N/A by ¥15.18.

Is Kohjin Bio Co.,Ltd. overvalued?

According to Wall Street analysts Kohjin Bio Co.,Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Kohjin Bio Co.,Ltd. pay dividends?

Kohjin Bio Co.,Ltd. pays a Notavailable dividend of ¥24 which represents an annual dividend yield of 1.62%. See more information on Kohjin Bio Co.,Ltd. dividends here

What is Kohjin Bio Co.,Ltd.’s EPS estimate?

Kohjin Bio Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kohjin Bio Co.,Ltd. have?

Kohjin Bio Co.,Ltd. has 5,111,600 shares outstanding.

What happened to Kohjin Bio Co.,Ltd.’s price movement after its last earnings report?

Kohjin Bio Co.,Ltd. reported an EPS of ¥15.18 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.548%.

Which hedge fund is a major shareholder of Kohjin Bio Co.,Ltd.?

Currently, no hedge funds are holding shares in JP:177A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kohjin Bio Co.,Ltd.

Kohjin Bio Co., Ltd. manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for virus and recombinant protein production, hybridoma, human lymphocyte culture, and insect cell lines; gas permeable cell culture bags and other materials; cryopreservation agent of cells; medium supplements; normal human cells; normal human cell mediums; ES cell mediums; in-vitro fertilization and early embryo culture kits; and other culture and related products, such as supplements, cell separation solutions, physiological salt solutions, and research reagents. The company also offers clinical microbiology culture mediums for gram positive cocci, gram negative bacteria, and susceptibility testing; general differential, anaerobic growth, and fungal mediums; tube mediums for confirmation and expansion; microbiology culture mediums for food, such as mediums for sterilization test, E. coli and coliform bacteria, staphylococcus spp., bacillus cereus, and vibrio parahaemolyticus; culture mediums for determining total viable cell count; and campylobacter and fungal mediums. In addition, the company offers normal human blood, serum, and plasma; pathological human serum; preserved animal blood; defibrinated and hemolyzed animal blood; animal serum and plasma; and other custom-designed products, such as eagle medium. Further, the company engages in the production and sale of laboratory animal, sale of medical equipment, trust of animal immunization and antibody preparation, and import and export of products and raw materials. The company was formerly known as Kohjin Co.,Ltd and changed its name to Kohjin Bio Co., Ltd. in 1989. The company was incorporated in 1981 and is based in Sakado, Japan.